New blood substitutes: Physiology and clinical impact

Problems in Anesthesia

Volumn 11, Issue 4, 1999, Pages 471-482

  Kramer, George C ^a   Poli De Figueiredo, Luiz F ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROCARBON; HEMOGLOBIN; PLASMA SUBSTITUTE;

BLOOD SUBSTITUTION; BLOOD TRANSFUSION; HUMAN; OXYGEN AFFINITY; OXYGEN TENSION; OXYGEN TRANSPORT; REVIEW; TREATMENT INDICATION; VISCOSITY;

EID: 0033427653     PISSN: 08894698     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Sloan EP, Koenigsberg MD, Bickell WH, et al. The use of diaspirin cross-linked hemoglobin (DCLHb) solution in the hospital management of hemorrhagic shock [abstract]. Acad Emerg Med 1995;2:78.
2. Proceedings of IBC's conference on blood substitutes and related products. Cambridge, MA, 1997.
3. Kaufman RJ. Clinical development of perfluorocarbon-based emulsions as red cell substitutes. In: Blood Substitutes: Physiological Basis of Efficacy. Winslow R, Vandegriff K, Intaglietta M, eds. Boston, MA: Birkhäuser; 1995:53-75.
4. Faithfull NS. Mechanisms and efficacy of fluorochemical oxygen transport and delivery. Artif Cells Blood Substit Immobil Biotechnol 1994;22:181-197.
5. Cochran RP, Kunzelman KS, Vocelka CR, Akimoto H, Thomas R, Soltow LO. Perfluorocarbon emulsion in the cardiopulmonary bypass prime reduces neurologic injury. Ann Thorac Surg 1997;64:1527.
6. Dietz NM, Joyner MJ, Warner MA. Blood substitutes: fluids, drugs, or miracle solutions? Anesth Analg 1996;82:390-405.
7. Rudolph AS. Encapsulation of hemoglobin in liposomes. In: Blood Substitutes: Physiological Basis of Efficacy. Winslow RM, Vandegriff KD, Intaglietta M, eds. Boston, MA: Birkäuser; 1995:90-104.
8. Hint H. Relationships between the chemical and physiochemical properties of dextran and its pharmacological effects. In: Dextrans: Current Concepts of Basic Actions and Clinical Applications. Derrick JR, Guest MM, eds. Springfield, IL: Charles C. Thomas; 1971:3-26.
9. Kramer GC, Elgjo GI, Poli de Figueiredo LF, Wade CE. Hyperosmotic-hyperoncotic solutions. Baillière's Clin Anaesthesiol 1997;11:143-161.
10. Tsai AG, Kerger H, Intaglietta M. Microcirculatory consequences of blood substitution with αα-hemoglobin. In: Blood Substitutes: Physiological Basis of Efficacy. Winslow RM, Vandegriff KD, Intaglietta M, eds. Boston, MA: Birkhäuser; 1995:155-174.
11. Intaglietta M. Blood viscosity and microvessel wall gradients in the use of artificial blood. Int J Microcirc Clin Exp 1996;16:37.
12. Vandegriff KD, Winslow RM. A theoretical analysis of oxygen transport: a new strategy for the design of hemoglobin-based red cell substitutes. In: Blood Substitutes: Physiological Basis of Efficacy. Winslow RM, Vandegriff KD, Intaglietta M, eds. Boston, MA: Birkhäuser; 1995:142-154.
13. Conhaim RL, Cooler SD, McGrath AM, DeAngeles DA, Myers GA, Harms BA. Filtration of diaspirin crosslinked hemoglobin into lung and soft tissue lymph. Am J Physiol 1998;158:1204-1212.
14. Poli de Figueiredo LF, Elgjo GI, Mathru M, ES Rocha, Kramer GC. Hypertonic acetate-alpha alpha hemoglobin for small volume resuscitation of hemorrhagic shock. Artif Cells Blood Substit Immobil Biotechnol 1997;25:61-73.
15. Rhea G, Bodenham A, Mallick A, Przybelski R, Daily E. Vasopressor effects of diaspirin cross-linked hemoglobin (DCLHb) in critically ill patients [abstract]. Crit Care Med 1996;24:A39.
16. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
17. Katsuyama SS, Cole DJ, Drummond JC, Bradley K. Nitric oxide mediates the hypertensive response to a modified hemoglobin solution (DCLHb) in rats. Artif Cells Blood Substit Immobil Biotechnol 1994;22:1-7.
18. Sharma AC, Singh G, Gulati A. Role of NO mechanism in cardiovascular effects of diaspirin cross-linked hemoglobin in anesthetized rats. Am J Physiol 1995;269:H1379-H1388.
19. Schultz SC, Hamilton INJ, Malcolm DS. Use of base deficit to compare resuscitation with lactated Ringer's solution, Haemaccel, whole blood, and diaspirin cross-linked hemoglobin following hemorrhage in rats. J Trauma 1993;35:619-625.
20. Schultz SC, Grady B, Cole F, Hamilton I, Burhop K, Malcolm DS. A role for endothelin and nitric oxide in the pressor response to diaspirin cross-linked hemoglobin. J Lab Clin Med 1993;122:301-308.
21. Poli de Figueiredo LF, Mathru M, Jones JR, Solanki D, Kramer GC. Inhaled nitric oxide reverses cell-free hemoglobin-induced pulmonary hypertension and decreased lung compliance. Crit Care Med 1997;1:111-116.
22. de Figueiredo LF, Mathru M, Solanki D, Macdonald VW, Hess J, Kramer GC. Pulmonary hypertension and systemic vasoconstriction may offset the benefits of acellular hemoglobin blood substitutes. J Trauma 1997;42:847-854.
23. Malcolm DS, Hamilton INJ, Schultz SC, Cole F, Burhop K. Characterization of the hemodynamic response to intravenous diaspirin crosslinked hemoglobin solution in rats. Artif Cells Blood Substit Immobil Biotechnol 1994;22:91-107.
24. Gould SA, Moss GS. Clinical development of human polymerized hemoglobin as a blood substitute. World J Surg 1996;20:1200-1207.
25. Kasper SM, Walter M, Grune F, Bischoff A, Erasmi H, Buzello W. Effects of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg 1996;83:921-927.
26. Gulati A, Sharma AC, Singh G. Role of endothelin in the cardiovascular effects of diaspirin crosslinked and stroma reduced hemoglobin. Crit Care Med 1996;24:137-147.
27. Garrioch M, Larbuisson R, Brichant JF, Lamy M, Daily E, Przybelski R. The hemodynamic effects of diaspirin cross-linked hemoglobin (DCLHb) in the operative setting [abstract]. Crit Care Med 1996;24:A39.
28. Su D, Roth RI, Yoshida M, Levin J. Hemoglobin increases mortality from bacterial endotoxin. Infect Immun 1997;65:1258-1266.
29. Aranow JS, Wang H, Zhuang J, Fink MP. Effect of human hemoglobin on systemic and regional hemodynamics in a porcine model of endotoxemic shock. Crit Care Med 1996;24:807-814.
30. Crowley JP, Metzger J, Gray A, Pivacek LE, Cassidy G, Valeri CR. Infusion of stroma-free cross-linked hemoglobin during acute gram-negative bacteremia. Circ Shock 1993;41:144-149.
31. Hughes GSJ, Antal EJ, Locker PK, Francom SF, Adams WJ, Jacobs EEJ. Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans. Crit Care Med 1996;24:756-764.
32. Frankel HL, Nguyen HB, Shea-Donohue T, Aiton LA, Ratigan J, Malcolm DS. Diaspirin cross-linked hemoglobin is efficacious in gut resuscitation as measured by a GI tract optode. J Trauma 1996;40:231-240.
33. Siegel JH, Fabian M, Smith JA, Costantino D. Use of recombinant hemoglobin solution in reversing lethal hemorrhagic hypovolemic oxygen debt shock. J Trauma 1997;42:199-212.
34. Tsai AG, Friesenecker B, Winslow RM, Intaglietta M. Functional capillary density changes during blood substitution with alpha alpha Hb and dextran 70: influence on oxygen delivery. Artif Cells Blood Substit Immobil Biotechnol 1994;22:841-847.
35. Nolte D, Steinhauser P, Pickelmann S, Berger S, Hartl R, Messmer K. Effects of diaspirin-cross-linked hemoglobin (DCLHb) on local tissue oxygen tension in striated skin muscle: an efficacy study in the hamster. J Lab Clin Med 1997;130:328-338.
36. Baxter Healthcare. Press releases. Baxter Healthcare Corp, Press Release, PR Newswire, March 31, 1998,
37. 'Baxter Ends US Trauma Study of HemAssist' and Baxter Healthcare Corp, Press Release, PR Newswire, September 16, 1998,
38. 'Baxter to Focus on Next-Generation Oxygen-Carrying Therapeutics; Decision Will End Clinical Development of First-Generation Program,' 1998.
39. Gould SA, Moore EE, Moore FA, et al. Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery. J Trauma 1997;43:325-331.
40. Lessen R, Williams M, Setzer J. A safety study of human recombinant hemoglobin for intraoperative transfusion therapy [abstract]. Artif Cells Blood Substit Immobil Biotechnol 1996;24:379.
41. Leone BJ, Chuey C, Gleason D. Can recombinant human hemoglobin make ANH more effective? [abstract] Artif Cells Blood Substit Immobil Biotechnol 1996;24:379.
42. Fischer SF, Bone HG, Powell WC, McGuire R, Traber DL. Pyridoxalated hemoglobin polyoxyethylene conjugate does not restore hypoxic pulmonary vasoconstriction in ovine sepsis. Crit Care Med 1997;25: 1151-1159.
43. Cole DJ, Nary JC, Drummond JC, Patel PM, Jacobsen WK. Alpha-alpha diaspirin crosslinked hemoglobin, nitric oxide, and cerebral ischemic injury in rats. Artif Cells Blood Substit Immobil Biotechnol 1997;25: 141-152.
44. Chang TM. Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties. Nat Biotechnol 1998;16:621-622.
45. Simoni J, Simoni G, Lox CD, Prien SD, Shires GT. Modified hemoglobin solution, with desired pharmacological properties, does not activate nuclear transcription factor NF-kappa B in human vascular endothelial cells. Artif Cells Blood Substit Immobil Biotechnol 1997;25:193-210.
46. Rabinovici R, Rudolph AS, Vernick J, Feuerstein G. A new salutary resuscitative fluid: liposome encapsulated hemoglobin/hypertonic saline solution. J Trauma 1993; 35:121-126.
47. Runge TM, Mcginity JW, Frisbee SE, et al. A hyperosmolar oxygen yielding blood substitute for cardiopulmonary bypass [abstract]. Artif Cells Blood Substit Immobil Biotechnol 1994;22:A154.